Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Moodys
McKesson
Harvard Business School
Baxter

Last Updated: December 6, 2022

Details for New Drug Application (NDA): 050790


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 050790 describes RESTASIS MULTIDOSE, which is a drug marketed by Allergan and is included in one NDA. It is available from five suppliers. There are ten patents protecting this drug. Additional details are available on the RESTASIS MULTIDOSE profile page.

The generic ingredient in RESTASIS MULTIDOSE is cyclosporine. There are eighteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
Summary for 050790
Tradename:RESTASIS MULTIDOSE
Applicant:Allergan
Ingredient:cyclosporine
Patents:10
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 050790
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790 NDA Allergan, Inc. 0023-5301 0023-5301-05 1 BOTTLE in 1 CARTON (0023-5301-05) > 5.5 mL in 1 BOTTLE
RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790 NDA Allergan, Inc. 0023-5301 0023-5301-08 1 BOTTLE in 1 CARTON (0023-5301-08) > 5.5 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:EMULSION;OPHTHALMICStrength0.05%
Approval Date:Dec 23, 2002TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:EMULSION;OPHTHALMICStrength0.05%
Approval Date:Oct 27, 2016TE:RLD:Yes
Patent:See Plans and PricingPatent Expiration:Feb 25, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:See Plans and PricingPatent Expiration:Apr 16, 2032Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 050790

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 See Plans and Pricing See Plans and Pricing
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Merck
Baxter
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.